More recently, Ciarlantini and colleagues identified a new family of chemical inhibitors against Rac1–GEF interaction that exhibited significant anti-proliferative activities in vitro and in a lung cancer animal model [52]. This evidence concerns the gene RAC1 and lung carcinoma.